Thierry Bernard joins Bruker (NASDAQ: BRKR) Board as new director

Rhea-AI Filing Summary

Bruker Corporation has expanded its Board of Directors to twelve members and appointed Thierry L. Bernard as a Class III director, effective April 1, 2026. He will serve until the 2027 Annual Meeting of Stockholders.

Bernard is currently CEO and Managing Director of QIAGEN N.V., with a previously announced transition plan under which he will step down once a successor is appointed. His background spans senior roles at bioMérieux and other international life-science companies, as well as board leadership at AdvaMedDx and Neogen Corporation. His compensation as a non-employee director will match Bruker’s existing director compensation program, and the company states there are no related-party transactions requiring disclosure. Bruker will later disclose his Board committee assignments.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Board size: 12 directors Initial term end: 2027 Annual Meeting QIAGEN tenure start: 2015 +1 more

4 metrics

Board size 12 directors Total Bruker directors after adding Thierry L. Bernard

Initial term end 2027 Annual Meeting End of Thierry L. Bernard’s current Board term

QIAGEN tenure start 2015 Year Bernard joined QIAGEN to lead molecular diagnostics

QIAGEN CEO appointment 2019 Year Bernard was named CEO of QIAGEN

Key Terms

Mandatory Convertible Preferred Stock, Class III, Item 404(a) of Regulation S-K, forward-looking statements, +1 more

5 terms

Mandatory Convertible Preferred Stock financial

"6.375% Mandatory Convertible Preferred Stock, Series A, $0.01 par value"

A mandatory convertible preferred stock is a type of investment that pays regular income like a preferred share but is designed to automatically turn into a set number of common shares at a future date, much like a timed coupon that becomes company ownership. It matters to investors because it combines a near-term income stream with a guaranteed future increase in the company’s share count, which can dilute existing owners and change earnings-per-share and voting balance.

Class III regulatory

"additional director assigned to Class III, and appointed Thierry L. Bernard"

Class III is the highest regulatory category for medical devices, covering products that support or sustain life, are implanted, or pose the greatest potential risk; these items must undergo extensive clinical testing and formal regulatory review before they can be sold. For investors, Class III status means longer timelines, higher development costs and greater approval risk, but successful clearance can yield strong market protection and sizable returns—like a product that needs a full road-test and inspection before it can be widely used.

Item 404(a) of Regulation S-K regulatory

"any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K"

forward-looking statements regulatory

"Any forward-looking statements contained herein are based on current expectations"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Annual Meeting of Stockholders financial

"serve as a director until the 2027 Annual Meeting of Stockholders"

Understanding 8-K Material Events →

false000110935400011093542026-04-012026-04-010001109354brkr:SixPointThreeSevenFivePercentageMandatoryConvertiblePreferredStockSeriesAMember2026-04-012026-04-010001109354us-gaap:CommonStockMember2026-04-012026-04-01

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 1, 2026

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	000-30833	04-3110160
(State or other jurisdiction of	(Commission	(I.R.S. Employer
incorporation)	File number)	Identification No.)

40 Manning Road

Billerica, MA 01821

(Address of principal executive offices) (Zip Code)

(978) 663-3660

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, $0.01 par value per share		BRKR		The Nasdaq Global Select Market
6.375% Mandatory Convertible Preferred Stock, Series A, $0.01 par value per share		BRKRP		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Section 5 - Corporate Governance and Management

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) Election of New Director

On March 27, 2026, the Board of Directors (the “Board”) of Bruker Corporation (the “Company”) approved an increase in the number of directors to expand the size of the Board by one director to a total of twelve directors, with such additional director assigned to Class III, and appointed Thierry L. Bernard to fill the newly created vacancy on the Board, effective as of April 1, 2026. Mr. Bernard will initially serve as a director until the 2027 Annual Meeting of Stockholders.

Mr. Bernard currently serves as Chief Executive Officer (“CEO”) and Managing Director of QIAGEN N.V. (NYSE: QGEN) (“QIAGEN”). In November 2025, QIAGEN announced a CEO transition plan whereby Mr. Bernard will step down as CEO and Managing Director once his successor is appointed. Mr. Bernard joined QIAGEN in February 2015 to lead its growing molecular diagnostics business and was named Chief Executive Officer in March 2020 after serving in this role on an interim basis since October 2019 and became a member of its managing board in 2021. Previously, he held roles of increasing responsibility during 15 years with bioMérieux SA, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. He also held senior management roles in several other leading international companies. In March 2023, he was named Chair of the AdvaMedDx Board of Directors, a U.S. industry trade association, and joined the board of directors of Neogen Corporation (NASDAQ: NEOG) in 2024. Mr. Bernard has earned degrees and certifications from Sciences Po, LSE, the College of Europe, Harvard Business School, Centro de Comercio Exterior de Barcelona and has been appointed Conseiller du Commerce Extérieur by the French government.

Mr. Bernard’s compensation for services as a director will be consistent with that of the other non-employee directors of the Company, as described under “Director Compensation” in the Company’s definitive proxy statement with respect to the 2025 Annual Meeting of Stockholders, filed with the Securities and Exchange Commission on April 11, 2025. There are no other arrangements or understandings between Mr. Bernard and any other person pursuant to which he was elected as a director, and Mr. Bernard is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K.

The Company will file an amended Form 8-K to disclose Mr. Bernard's committee assignments once determined.

A copy of the press release announcing Mr. Bernard's appointment is attached to this report as Exhibit 99.1.

Section 9 – Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d)	Exhibits.
	Number		Description
	99.1		Press release dated April 1, 2026.
	104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRUKER CORPORATION (Registrant)
Date: April 1, 2026	By:	/s/ THOMAS M. BURES
		Thomas M. Bures
		Chief Accounting Officer

Mr. Bernard currently serves as Chief Executive Officer of QIAGEN N.V. He joined QIAGEN in 2015 to lead its growing molecular diagnostics business and was named Chief Executive Officer in 2019. He has announced his intention to step down as CEO upon the appointment of a successor.

Previously, Mr. Bernard held roles of increasing responsibility during 15 years with bioMérieux SA, including as Corporate Vice President for Global Commercial Operations, Investor Relations and the Greater China Region. He also held senior management roles in several other leading international companies.

Exhibit 99.1

Bruker Announces Appointment of Thierry Bernard to its Board of Directors

BILLERICA, Massachusetts - April 1, 2026 – Bruker Corporation (Nasdaq: BRKR) announces the appointment of Mr. Thierry L. Bernard to serve on its Board of Directors, effective as of today. Mr. Bernard is an international life-science tools and diagnostics industry executive with decades of relevant leadership, strategic and operational experience.

Frank H. Laukien, the Chairman, President and CEO of Bruker Corporation, stated: “Bruker is delighted that Thierry is joining our Board. I have admired his successful track record, astute strategic initiatives, and outstanding execution for many years, and I am convinced that Thierry will be an excellent addition to our Board of Directors as we further develop our leadership position in life-science research, biopharma, and diagnostic solutions in the post-genomic era, and aim for profitable growth and rapid margin expansion to enhance stakeholder value.”

In 2023, Mr. Bernard was named Chair of the board of directors of the U.S. trade industry association AdvaMedDx and joined the board of directors of Neogen Corporation in 2024. He has earned degrees and certifications from Sciences Po Paris, the London School of Economics, the College of Europe, Harvard Business School and Centro de Comercio Exterior de Barcelona.

“I am very pleased to join Bruker’s Board of Directors. I have long admired its significant contributions to scientific research and improving patient outcomes,” said Thierry Bernard. “Bruker’s high-performance technologies and global footprint position it well to enable a deeper understanding of biology to support more precise diagnostics, more effective therapies and ultimately better healthcare. I look forward to supporting its continued development and commitment to long-term value creation.”

About Bruker Corporation – Leader of the Post-Genomic Era

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity,

and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.For more information, please visit www.bruker.com.

Forward-Looking Statements

Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, those risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2025, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Investor Contact:
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

FAQ

What did Bruker Corporation (BRKR) announce in this 8-K filing?

Bruker Corporation expanded its Board and appointed Thierry L. Bernard as a new director. The Board increased its size to twelve members and named Bernard a Class III director, effective April 1, 2026, with a term running until the 2027 Annual Meeting of Stockholders.

Who is Thierry L. Bernard, the new Bruker (BRKR) board member?

Thierry L. Bernard is an experienced life-science tools and diagnostics executive. He serves as CEO and Managing Director of QIAGEN N.V., previously led QIAGEN’s molecular diagnostics business, held senior roles at bioMérieux, and chairs the AdvaMedDx board while serving on Neogen Corporation’s board.

How long will Thierry Bernard serve on Bruker’s Board of Directors?

Thierry Bernard will initially serve on Bruker’s Board until the 2027 Annual Meeting. He has been appointed as a Class III director, filling a newly created seat after the Board increased its size from eleven to twelve directors to add his position.

How will Thierry Bernard be compensated as a Bruker (BRKR) director?

Thierry Bernard’s compensation will match that of Bruker’s other non-employee directors. The company references its director compensation program described in its definitive proxy statement for the 2025 Annual Meeting of Stockholders filed with the SEC on April 11, 2025.

Does Bruker disclose any related-party transactions involving Thierry Bernard?

Bruker states there are no related-party transactions involving Thierry Bernard requiring disclosure. The company notes he is not party to any transaction with Bruker that would require disclosure under Item 404(a) of Regulation S-K, indicating no material related-party dealings are reported.

Will Thierry Bernard serve on any Bruker Board committees?

Bruker has not yet disclosed Thierry Bernard’s committee assignments. The company notes it will file an amendment once his specific committee roles on the Board of Directors are determined, indicating that those governance details will be provided in a later filing.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 15.5 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 49.7 KB